Eurovet’s highly successful Research & Development (R&D) department employs around 16 staff, while a further 16 people work for us in external laboratories at home and abroad. Our R&D team consistently succeeds in keeping our new product pipeline filled.

Ideas
Our new projects are almost exclusively based on existing molecules. We focus chiefly on new applications for existing active ingredients, new or improved drug administration methods, new indications, shorter withdrawal periods and improved animal-friendly formulations. We develop our own new ideas by using information collected in the field. To that end, we listening carefully to our end users: animal owners and especially veterinarians.

Development
Our team of pharmacists, chemists, veterinarians and analysts, all of whom are specialists in varying subjects, formulates rough ideas which are eventually refined into high-quality Eurovet products. When we start the creative process, we consider not only the quality and registration requirements for the end product but also whether it will be affordable. When we need outside knowledge and experience we call in both domestic and international specialists for help. During the development process we are often confronted with complex problems. To solve them, we sometimes go back a few steps in the development process so as to guarantee the desired level of quality. This is one of the factors that can cause the timeframe from idea to finished product to vary from three to six years or more.

Registration
Before a new product can enter the European market, it must first be authorised. Authorisation is the set of activities aimed at acquiring a market licence and maintaining that licence once it has been granted. We have a great deal of experience in this area - in the complex world of registration requirements both within and outside of Europe, we know exactly what needs to be done to register a product. In the past few years, Eurovet has not only successfully completed countless domestic procedures but also twelve European registration procedures. However, we mostly focus on Northwest-Europe and on our domestic markets of Germany, the Netherlands and Belgium in particular.

Our successes over the past few years have resulted in a healthy mix of products for companion and farm animals – from sedatives for cats and horses to painkillers for pigs and calves, and from hormone preparations to fight canine thyroid disease to hoof treatment sprays for sheep and cattle. We also use different registration routes. Sometimes the request is based entirely on our own work; in other cases we refer as much as possible to other registration files.

Conclusion
Successful R&D requires excellent client communication, but also a skill for recognising new markets and applications. Our scientific staff and resourceful laboratory assistants consistently turn good ideas into high-quality end products.

Successful registration comes down to teamwork amongst top players who base their work on excellent files, profound knowledge of the registration requirements and good contacts within the registration authorities.